Skip to main content

Advertisement

SpringerLink
Log in

Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

A Correction to this article was published on 28 December 2023

This article has been updated

Abstract

The purpose of this report is to describe the efficacy of sacubitril/valsartan in 5 hemodialysis patients with hypertension, including a patient with heart failure with reduced ejection fraction (HFrEF) and a patient with preserved ejection fraction (HFpEF) focused on the functional changes in the heart. We switched from angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) to sacubitril/valsartan and compared blood pressure post dialysis, N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels and the findings of echocardiography for a period of 6 months. A month after the initiation of sacubitril/valsartan, there was improvement of symptoms and blood pressure post-dialysis, the NT-pro-BNP levels decreased from 23,132.2 ± 16,561.3 pg/mL to 8327 ± 3334.3 pg/mL, and the echocardiography findings showed a decrease in the left atrial dimension from 37.7 ± 5.7 mm to 33 ± 4.9 mm and an increase in the left ventricular ejection fraction from 58.2 ± 16.9% to 66.4 ± 15.0%. These results were sustained for up to 6 months. Also, blood pressure post-dialysis changed from 164 ± 11/77 mmHg to 150 ± 13/72 mmHg over the 6-month period. There were no side effects, such as hyperkalemia and lymphoedema. In conclusion, 5 patients had hypertension, including 2 patients with heart failure. Sacubitril/valsartan improved blood pressure post-dialysis, heart failure symptoms, NT-pro- BNP, the left atrial dimension, the left ventricular ejection fraction, and E/e’, E/A found via echocardiography for a 6-months period. Treatment with sacubitril/valsartan was effective in hemodialysis patients in the cardiac function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

References

  1. JSDT. http://www.jsdt.or.jp/info/4032.html.online. Accessed 2021

  2. Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681–3. https://doi.org/10.1093/eurheartj/ehaa1012.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Heyse A, Manhaeghe L, Mahieu E, Vanfraechem C, Van Durme F. Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail. 2019;6:1331–3. https://doi.org/10.1002/ehf2.12544.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lee S, Oh J, Kim H, Ha J, Chun KH, Lee CJ, Park S, Lee SH, Kang SM. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020;7:1125–9. https://doi.org/10.1002/ehf2.12659.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Feng Y, Li W, Liu H, Chen X. Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: a case report. Medicine (Baltimore). 2022;101: e29186. https://doi.org/10.1097/md.0000000000029186.

    Article  PubMed  CAS  Google Scholar 

  6. Lihua W, Cheng L, Chen H, Wei F, Jiang A. Use of angiotensin receptor neprilysin inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction, real-world experience from a single center. Iran J Kidney Dis. 2021;15:288–99. https://doi.org/10.52547/ijkd.5875.

    Article  PubMed  Google Scholar 

  7. Kong P, Dou Y, Wang X, Xiao J, Zhao Z. The effect of sacubitril/valsartan in a dialysis patient with severe heart failure. Case Rep Clin Med. 2021;10:197–202. https://doi.org/10.4236/crcm.2021.107025.

    Article  Google Scholar 

  8. Daimon S, Yasuda M, Maeda K. Effect of sacubitril/valsartan on cardiac function in hemodialysis patients. Ther Apher Dial. 2021;26:244–5. https://doi.org/10.1111/1744-9987.13715.

    Article  PubMed  Google Scholar 

  9. Iwashima Y, Fukushima H, Horio T, Rai T, Ishimitsu T. Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension. J Clin Hypertens (Greenwich). 2023;25:304–8. https://doi.org/10.1111/jch.14635.

    Article  PubMed  CAS  Google Scholar 

  10. Daimon S, Sakamoto Y, Yasuda M, Nishitani M. Long-term cardiac effect of sacubitril-valsartan in hemodialysis patients with a reduced ejection fraction after aortic valve replacement for aortic stenosis: a case report with literature review. Ren Replace Ther. 2023;9:19. https://doi.org/10.1186/s41100-023-00473-4.

    Article  Google Scholar 

  11. D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017;19:710–7. https://doi.org/10.1002/ejhf.799.

    Article  PubMed  CAS  Google Scholar 

  12. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077.

    Article  PubMed  CAS  Google Scholar 

  13. Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD. Association of change in N-Terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085–95. https://doi.org/10.1001/jama.2019.12821.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, Butler J, Piña IL, Ibrahim NE, Abbas C, Burnett JC Jr, Solomon SD, Januzzi JL. Atrial natriuretic peptide and treatment with sacubitril/valsartan in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;9:127–36. https://doi.org/10.1016/j.jchf.2020.09.013.

    Article  PubMed  Google Scholar 

  15. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type peptide, high sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem. 2004;50:2279–85.

    Article  PubMed  CAS  Google Scholar 

  16. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael FG, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco PM, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association. Eur J Heart Fail. 2021;23:352–80. https://doi.org/10.1002/ejhf.2115.

    Article  PubMed  Google Scholar 

  17. Naito T, Masaki T, Shimizu Y, Ogawa T, Ochiai M, Hamaguchi N, Hirashio S, Doi T, Yokoyama Y, Yorioka N. N-terminal pro brain natriuretic peptide predicts hospitalization of hemodialysis patients for cardiovascular disease. Nihon Jinzo Gakkai Shi. 2011;53:633–41.

    PubMed  CAS  Google Scholar 

  18. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284–9. https://doi.org/10.1016/s0002-9149(02)02864-3.

    Article  PubMed  Google Scholar 

  19. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Arango JL, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352–61. https://doi.org/10.1161/circulationaha.119.044586.

    Article  PubMed  Google Scholar 

  20. Feng Z, Wang X, Zhang L, Apaer R, Xu L, Ma J, Li X, Che H, Tang B, Xiong Y, Xia Y, Xiao J, Su X, Wang Y, Dou X, Chen J, Mei L, Xue Z, Kong Y, Li S, Zhang H, Lin T, Wen F, Fu X, Tao Y, Fu L, Li Z, Huang R, Ye Z, He C, Shi W, Liang X, Ke G, Liu S. Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in maintenance hemodialysis patients with heart failure. Blood Purif. 2021;51:270–9. https://doi.org/10.1159/000519643.

    Article  PubMed  CAS  Google Scholar 

  21. Gan L, Lyu X, Yang X, Zhao Z, Tang Y, Chen Y, Yao Y, Hong F, Xu Z, Chen J, Gu L, Mao H, Liu Y, Sun J, Zhou Z, Du X, Jiang H, Li Y, Sun N, Liang X, Zuo L. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus. Front Med (Lausanne). 2022;9: 877237.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all the staff members working at Yonabaru Central Hospital, Nephrology and Dialysis.

Funding

This study was not supported by any grants or funding.

Author information

Authors and Affiliations

  1. Department of Nephrology and Dialysis of Yonabaru Central Hospital, 2905, Yonabaru, Okinawa, Japan

    Noriko Kuwae

Authors
  1. Noriko Kuwae
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noriko Kuwae.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at the facility in which the studies were conducted (IRB approval number 2022 A-2) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication

Informed consent for publication was obtained from the individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In the original publication, the author found an error in the Fig. 1. The error is as below: EFrEF should read as HFrEF and EFpEF should read as HFpEF.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuwae, N. Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report. CEN Case Rep (2023). https://doi.org/10.1007/s13730-023-00833-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13730-023-00833-3

Keywords

Search

Navigation